Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GC33 in patients with advanced hepatocellular carcinoma
jRCT2080221218Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of codrituzumab in hepatocellular carcinoma (HCC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
codrituzumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221218.